Summary
Merck & Co., Inc. (MRK) has filed an 8-K report on March 23, 2011, detailing the termination of a material definitive agreement. Specifically, on March 21, 2011, Merck, Sanofi-Aventis, and their respective subsidiaries, entered into a Master Termination Agreement and Release. This agreement effectively terminates the Call Option Agreement and the Contribution Agreement that were established in 2009 and 2010, respectively. The original Call Option Agreement granted Sanofi-Aventis the right to conduct due diligence on Merck's animal health business and the option to acquire it. This acquisition would have resulted in a 50/50 joint venture in Merial, Merck's animal health subsidiary. The termination of these agreements signifies that this proposed transaction, which would have significantly altered the ownership structure of Merck's animal health business, will not proceed as previously planned. Investors should note that this development avoids a potentially complex restructuring of a key business segment.
Key Highlights
- 1Merck and Sanofi-Aventis have terminated their Call Option Agreement and related Contribution Agreement concerning Merck's animal health business.
- 2The termination was formalized on March 21, 2011, through a Master Termination Agreement and Release.
- 3This action effectively cancels the planned transaction where Sanofi-Aventis could have acquired Merck's animal health business in exchange for a 50% equity stake in Merial.
- 4No financial implications beyond the termination of these specific agreements were detailed in this filing.
- 5A joint news release announcing the termination was issued by Merck and Sanofi-Aventis on March 22, 2011.
- 6The company formerly known as Schering-Plough Corporation is referred to as Merck in the context of the Call Option Agreement.